Brief: Tcr² Therapeutics To Announce Complete Phase 1 Portion Of The Gavo-Cel Phase 1/2 Clinical Trial For Mesothelin-Expressing Solid Tumors
27/09/2022 21:23
Sept 27 (Reuters) - TCR2 Therapeutics Inc TCRR.O :
* TCR² THERAPEUTICS TO ANNOUNCE COMPLETE PHASE 1 PORTION OF
THE
GAVO-CEL PHASE 1/2 CLINICAL TRIAL FOR MESOTHELIN-EXPRESSING
SOLID TUMORS
Source text for Eikon: ID:nGNXc0HqDl
Further company coverage: TCRR.O
Recent news on TCR2 Therapeutics
See all newsBrief: TCR2 Therapeutics Entered Into An Assignment Of Lease Agreement With Astrazeneca
TCR2 Therapeutics falls on bigger-than-expected Q1 loss
Brief: Tcr² Therapeutics Reports Q1 2023 Financial Results And Provides Corporate Update
TCR2 Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
TCR2 Therapeutics Inc expected to post a loss of 68 cents a share - Earnings Preview